A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07239167

Enrollment

500

Registered

2025-11-20

Start date

2025-06-05

Completion date

2035-05-05

Last updated

2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Syndrome, Obesity (Disorder), Obesity & Overweight, Weight Loss

Brief summary

This prospective cohort study collected baseline data and followed up obese patients at their first visit to a weight loss clinic. The study examined the impact of various predictors and biomarkers on weight loss outcomes, aiming to establish an evidence-based foundation for personalized weight loss treatment. Participants underwent a battery of measurements and questionnaires, including height, weight, waist circumference, blood pressure, blood tests, and questionnaires addressing diet, exercise, stress, sleep, measure handgrip strength ,and psychological well-being.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Adults aged 18 years or older, regardless of gender. 2. Body mass index (BMI) ≥ 27 kg/m², or ≥ 24 kg/m² with one or more obesity-related comorbidities. 3. Willing to undergo any form of weight loss intervention. 4. Able to read and understand Chinese, willing to complete questionnaires, blood tests, and follow-up follow-up. 5. Voluntarily consent to participate and be willing to complete the subject consent form.

Exclusion criteria

1. Pregnant or breastfeeding women. 2. Individuals with significant mental illness (e.g., schizophrenia, severe depression) or cognitive impairment that may affect their ability to consent or cooperate with the study. 3. Individuals with severe organ dysfunction (e.g., end-stage renal disease, cirrhosis, congestive heart failure, etc.). 4. Individuals taking medications that significantly affect their weight (e.g., long-term steroids or antipsychotics) and cannot be discontinued. 5. Individuals deemed unsuitable for participation in this study by the study leader (e.g., individuals who are expected to be unable to complete follow-up).

Design outcomes

Primary

Measure	Time frame
Baseline data were collected and followed up during the subjects' initial visit to the weight loss clinic to establish an evidence-based basis for personalized weight reduction treatment.	Weight changes of subjects after 24 weeks, 48 weeks, 72 weeks, and 96 weeks.

Countries

Taiwan

Outcome results